Ananda Devices Inc.

Published purpose

The enterprise has developed a first-class, patent protected technology platform to produce human neuromuscular junction-on-a-chip. The technology has been validated by a leading pharmaceutical company to accelerate toxicity and efficacy tests leading to regulatory approval of two new therapeutic candidates. The FDA is collaborating to qualify this cutting-edge chip technology as a drug discovery tool to replace animal-based toxicity assays. The successful integration of the technology will directly impact drug development and toxicity testing, enhancing the FDA's regulatory processes, reviews, laboratory responses, and will significantly contribute in fortifying public health and biodefense readiness.